Sangamo Therapeutics Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sangamo Biosciences (SGMO) Tops Q3 EPS by 4c, Revs Beat
November 9, 2017 4:26 PM ESTSangamo Biosciences (NASDAQ: SGMO) reported Q3 EPS of ($0.15), $0.04 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $11.8 million versus the consensus estimate of $10.36 million.
GUIDANCE:
Sangamo Biosciences sees FY2017 revenue of $30-40 million, versus the consensus of... More
